Heart Drug Cuts Teen Heart Obstruction by 48mm Hg in Trial

Teens with a life-threatening inherited heart condition finally have hope beyond symptom management and risky surgery.

Researchers at Children's Hospital of Philadelphia just reported that mavacamten, a precision medicine drug, dramatically reduced dangerous heart obstruction in adolescents with hypertrophic cardiomyopathy (HCM). The results appeared in the New England Journal of Medicine and were presented at the American College of Cardiology's Annual Scientific Session in March 2026.

HCM is the most common inherited heart disease. It causes the heart muscle to thicken abnormally and become stiff, blocking blood flow and triggering chest pain, dizziness, shortness of breath, and potentially deadly complications like heart failure and sudden cardiac death.

Until now, doctors could only offer teens symptom-focused medications or invasive surgery. Neither addressed the root cause of the disease.

The global trial enrolled 44 teens between ages 12 and 17 with symptomatic obstructive HCM. Twenty-three received mavacamten while 21 got a placebo for 28 weeks, with neither families nor doctors knowing who got the real drug.

After 28 weeks, the results were striking. Teens taking mavacamten experienced a 48.5 mm Hg drop in heart obstruction during stress testing, while the placebo group showed virtually no change at just 0.5 mm Hg.

Side effects were similar in both groups, and all patients met key safety thresholds. The drug appeared both effective and safe for this age group, who typically have more severe disease than adults.

The Ripple Effect

The impact may extend far beyond easing symptoms. Blood markers indicating heart damage actually decreased in teens taking mavacamten but increased in those on placebo.

That pattern suggests something remarkable: the drug might not just manage symptoms but actually help damaged hearts heal over time. This could fundamentally change how doctors approach treating young patients.

"If these findings are confirmed with further research, we'll want to look at starting treatment in children sooner, before the heart has experienced years of damage," said lead author Dr. Joseph Rossano, Chief of Cardiology at Children's Hospital of Philadelphia.

If the FDA approves mavacamten for adolescents, it would become the first pediatric-specific targeted therapy for HCM. Families who've watched their children struggle with limited options would finally have a transformative treatment that addresses the disease at its biological root.

For kids born with HCM, the future just got brighter.